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Symptoms and activation of granulocytes and complement with two
dialysis membranes. Complement (C) activation, neutropenia, and mild
pulmonary dysfunction attend hemodialysis (HD) with cellophane [for
example, cuprophan (Cu)] membranes. While usually asymptomatic,
these phenomena may cause distress in patients with cardiopulmonary
disease, and "start-up" symptoms of HD might be mediated by C-
stimulated granulocytes (PMNs). Cellulose acetate (CA) hemodialysis
membranes have been devised and claimed more blood compatible than
Cu. In a blinded series of HD patients, pruritis, fatigue, and sense of
well-being were each scored statistically more favorably by the patients
during HD with CA than during HD with Cu (P < 0.05). Postulating that
less C activation might underlie the benefit, we showed that neutrope-
nia was less severe with CA (nadir 77.6% of initial count, 4 ssi) than
with Cu (38.3% 2.9; P <0.01). In vitro, incubation of CA membranes
with plasma led to less C3 conversion (20% vs. 40%), less PMN
aggregating activity (5.9 ZAP units vs. 36.3) and less decrement in CH0
(6.5% vs. 22%) than like incubations of Cu. C activation was also less
potent in vivo: During HD plasma C3a rose from a mean 401 ng/ml to a
peak 6,325 in patients on Cu dialyzers, but from 426 to only 3,637 in
patients on CA devices (P < 0.05). Time-course studies suggested CA
was initially as potent an activator as Cu but rapidly lost ability to
activate C, possibly because of saturation of C3b binding sites. As an
index of PMN activation, we also assayed plasma lactoferrin and found
levels significantly higher during Cu than CA dialysis. We conclude that
CA is better tolerated as a HD membrane than is Cu, and suggest
improved tolerance results from the lesser ability of CA to activate
plasma C and in turn to stimulate PMNs.
Symptbmes et activation des granulocytes et du complement avec deux
membranes dialyses. L'activation du complement (C), une neutropénie,
et un dysfonctionnement pulmonaire modéré se produisent en hémodia-
lyse (HD) avec des membranes de cellophane [par exemple, cupro-
phan (CU)]. Bien qu'habituellement asymptomatiques ces phéno-
ménes peuvent être a l'origine d'une détresse chez des malades atteints
de maladies cardio-pulmonaire, et les symptômes du "demarrage" de
l'HD pourrait étre médiés par des granulocytes stimulés par C (PMN).
Des membranes d'hemodialyse en acetate de cellulose (CA) ont etC
mises au point, et ont etC dites étre plus compatibles pour le sang que
Cu. Dans une sCrie en insu de patients en HD, Ic prurit, Ia fatigue, et Ia
sensation de bien-être ont été chacun statistiquement plus favorable
chez des patients pendant l'HD avec CA que pendant l'HD avec Cu (P
< 0,05). En postulant qu'une activation moindre du C pourrait étre a
l'origine de cette amelioration, nous avons montrC que Ia neutropenie
Ctait moms sévère avec CA (Nadir 77,6% du compte initial, 4 SEM)
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qu'avec Cu (38,3% 2,9; P < 0,01). In vitro, l'incubation de mem-
branes CA avec du plasma a conduit a une moindre conversion de C3
(20% contre 40%), a une moindre activité agrégeante de PMN (5,9
unites ZAP contre 36,3), et a une moindre diminution du CH50 (6,5%
contre 22%) que les incubations avec Cu. L'activation de C était
egalement moms puissante in vivo: Pendant l'HD, le C3a plasmatique
s'est élevé d'une moyenne de 401 ng/ml a un pic de 6 325 chez les
malades avec des dialyseurs en Cu, mais de 426 a seulement 3 637 chez
les malades avec des membranes en CA (P < 0,05). Des etudes en
fonction du temps ont suggCrC que CA etait initialement un activateur
aussi puissant que Cu mais que rapidement il perdait sa capacitC
d'activer, probablement en raison d'une saturation des sites de liaison
du C3b. Comme index d'activation PMN, nous avons egalement dose La
lactoferrine plasmatique et trouvC des niveaux significativement plus
élevés pendant La dialyse avec Cu qu'avec CA. Nous concluons que CA
est mieux tolCrC comme membrane de dialyse que Cu, et nous suggér-
ons que cette meilleure tolerance est Ic résultat d'une moindre capacité
du CA d'activer le C plasmatique, et a son tour de stimuler les PMN.
Profound neutropenia regularly attends the early phase of
hemodialysis using dialyzers with cellophane membranes [1—41.
This neutropenia is the result of complement activation which
occurs via the alternative pathway when plasma contacts the
cellophane membrane of the dialyzer [3]. Co-incident with the
neutropenia, mild pulmonary dysfunction is seen [4]; while
hypoxemia may be partially explained through gas exchange in
the dialyzer (and consequent hypoventilation) [5], changes also
occur in closing volumes and CO diffusion [4]. A similar pattern
of pulmonary dysfunction may be seen in other extracorporeal
circulations in which gas exchange does not occur [6].
The leukostasis and pulmonary dysfunction of early hemodi-
alysis are usually asymptomatic. However, an occasional pa-
tient with underlying cardiopulmonary disease may have overt
angina or dyspnea [4, 7, 8]. Further, some patients may have
such symptoms as urticaria, pruritis, or wheezing [9—Il]. It is
attractive to speculate that at least some of these "start-up"
symptoms may be in fact the result of complement activation
and resultant stimulation of granulocytes. Furthermore, a role
has been postulated for such phenomena in some of the long-
range complications of hemodialysis [7, 8].
In the past decade, dialysis membranes have been devised
which are claimed to be more "blood compatible" than cello-
phane; these have included membranes made of cellulose
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acetate and polyacrylonitrile, from which dialyzers have now
been made for clinical trials. Participating in early animal and
clinical trials of dialyzers with cellulose acetate membranes
(now available for clinical use), we had the impression that they
were better tolerated than cellophane (specifically Cupro-
phan) dialyzers [121 and therefore specifically studied their
clinical tolerance and their ability to activate complement and
granulocytes in a prospective fashion.
Methods
Patients. In an outpatient hemodialysis program at the Veter-
ans Administration Lakeside Medical Center, Chicago, Illinois,
thirteen maintenance hemodialysis patients routinely dialyzed
with cellulose acetate hemodialyzers participated with informed
consent in a blinded crossover study comparing dialyzers with
cuprophan or cellulose acetate membranes. Dialyzers of com-
parable surface area and configuration were used. The cellulose
acetate dialyzer used was the CDAK 4000(1.4 m2, Cordis-Dow
Corporation, Miami, Florida); the cuprophan dialyzer used was
the Travenol CF 1511 (1.2 m2, Travenol Laboratories, Deer-
field, Illinois). To assure that neither patient nor staff would
recognize the dialyzer in use on a given run, the device was
completely covered with aluminum foil. Twelve patients com-
pleted hemodialyses with each of the devices; six underwent
dialysis with cuprophan first and six with cellulose acetate first.
Patients were asked to complete questionnaires at the end of
dialysis treatments, concerning pruritis, fatigue, and sense of
well-being during the individual run. The nurses were asked to
record tolerance to treatment and instances of treatment inter-
vention. In a second phase of evaluation for differences in
leukopenia, complement activation and granulocyte activation,
both the CF 1511 and a second cuprophan dialyzer(Gambro 1.5
m2, Gambro AB, Wheeling, Illinois) were used.
Clinical blood samples. During hemodialysis, EDTA anti-
coagulated samples were obtained from each arm of the dialyz-
er circuit at various times. These were promptly centrifuged to
remove the cellular elements, and the plasmas were retained
frozen (—70°C) until assay. Assays performed away from the
center where dialysis was undertaken were performed on
EDTA anti-coagulated plasmas which were shipped frozen to
the laboratories at the University of Minnesota (granulocyte
aggregometry), San Diego Veterans Administration Hospital
(C3a and C5a) and Indiana University (lactoferrin),
respectively.
Complement assays. CH50 was measured by standard tech-
niques [13]. C3 conversion was detected immunoelectrophoreti-
cally as previously described [141; PMN aggregating activity
was used as a bioassay of C5a as previously described [15] and
was recorded as "ZAP units" (100 ZAP units equals the amount
of aggregating activity in fully zymosan-activated plasma) [16].
C3a and C5a were measured by a new radioimmunoassay
(DEC), as described elsewhere in detail [17].
Evidence of granulocyte activation. Peripheral neutrophil
counts were obtained by standard techniques during hemodialy-
sis. As a reflection of granulocyte activation (at least of
granulocyte activation adequate to provoke exocytosis), plasma
lactoferrin was measured using a radioimmunoassay (LAB) as
described elsewhere [181.
In vitro incubations. The in vitro potency of the two dialyzers
to activate plasma complement was assayed (by DEH) in a
Table 1. Symptoms during hemodialysis
Symptom scored° Cellulose acetateb Cuprophan P
Pruritis 75.0 (4.2) 63.5 (5.2) < 0.03
Well-being 71.2 (4.1) 55.0 (7.9) < 0.03
Fatigue 81.2 (5.6) 66.2 (9.6) = 0.08
° Symptoms were scored by patients on a 0 to 100 scale (0 = most
severe). The three rated symptoms were all scored as less severe during
cellulose acetate than during cuprophan hemodialysis. The numbers
displayed are mean scores.
b SE are in parentheses.
manner analogous to earlier studies [3, 6]. One gram of fibers
from a cuprophan hollow fiber dialyzer (Travenol CF) was
minced and incubated aseptically with 20 ml minimally heparin-
ized (1 U/mI) normal human plasma on a tipper for 30 mm at
37°C. These plasmas were then decanted and compared with
parallel blank incubations and with incubations of similarly
prepared cellulose acetate fibers (C-DAK 4000) for the follow-
ing evidence of complement activation: decrement in CH50, C3
conversion, and generation of PMN aggregating activity (see
above).
Results
Patient tolerance of dialyzers. Well-being, pruritis, and fa-
tigue at the end of treatment were graded better during cellulose
acetate hemodialysis than cuprophan hemodialysis by the ma-
jority of patients during the blinded study (Table 1, P <0.03, U-
test). More strikingly, code breaks and cross-over were re-
quested during the first 30 mm in three dialyses, all while the
cuprophan device was in use. In one patient hypotension,
nausea, vomiting, diarrhea, and pruritis were so severe that he
withdrew from the randomization; the dialysis run was complet-
ed with a cellulose acetate device with markedly improved
tolerance. Two other patients developed severe respiratory
symptoms requiring a code break and change to cellulose
acetate dialyzers; one of these had clinically quiescent asthma,
and his dialyzer reaction was followed by a period of difficult
asthma control ultimately requiring hospitalization. In two
other patients, chest pain, nausea, and vomiting occurred
during cuprophan hemodialysis, but did not preclude comple-
tion of the runs; no adverse reactions were recorded by nurses
during dialysis with cellulose acetate membranes. Other inter-
ventions (symptomatic treatment of chills, hypotension, and so
forth) were also somewhat more frequent during cuprophan
hemodialysis.
Neutropenia. Postulating that less complement activation
might underlie the clinical benefit seen with cellulose acetate
dialyzers, we first looked to see whether neutropenia (which is
presumably mediated by complement activation) was less se-
vere. Indeed, this was the case. In 25 patients undergoing
hemodialysis with cellulose acetate devices, the white count fell
an average of 22.4% (± 4% SEM). In contrast, the same patients,
when undergoing dialysis with cuprophan devices, experienced
a fall in the white count of 61.7% (± 2.9%; P < 0.01); several
patients experienced greater than an 80% fall in granulocyte
count. No statistically significant difference was observed be-
tween the two types of cuprophan devices.
Activation of plasma complement by dialyzer membranes in
vitro. In results analogous to earlier studies [3], the incubation
Fig. 1. Cellulose acetate as it generates less C5a (measured as PMN
aggregating activity) in plasma than does regenerated cellulose (Cu-
prophan). Vertical axis is an arbitrary scale of light transmission (T)
and reflects aggregation of a suspension of normal PMNs. The addition
of zymosan-activated plasma (top) produces a large aggregation wave,
reflecting the presence of large amounts of C5a; plasma incubated with
cuprophan (second tracing) produces a smaller wave; plasma incubated
with cellulose acetate (third tracing) produces an even smaller wave;
plasma incubated alone produces only a dilution artifact (bottom
tracing). Results were concordant for six plasma donors.
of cuprophan membranes with minimally heparinized plasma
resulted in a significant fall in CH50 (22% 6), (mean 140 to 107
hemolytic units) and the generation of substantial amounts of
granulocyte aggregating activity (36.3 ZAP units 9.6; Fig. I).
In contrast, plasma incubated with cellulose acetate fibers
showed only a 6.5% decrement in CH50 (± 2; mean 140 to 129
hemolytic units; P for the difference from cuprophan < 0.05),
and only 5.9 ZAP units of granulocyte aggregating activity
(± 2.25; P < 0.05). Concordantly, in each of six plasma donors
studied, incubation with cuprophan led to more extensive C3
conversion than parallel incubations with cellulose acetate (Fig.
2).
Complement activation during dialysis. Estimation of C5a
concentration in dialyzer arterial (afferent) lines by granulocyte
aggregometry did not show a convincing difference between the
two dialyzers. However, the levels of C5a were clustered near
the threshold of detection by that technique. We therefore
assayed C3a and C5a by radioimmunoassay, a newer technique
which provides greater sensitivity and objectivity; these sam-
ples were obtained from the venous (efferent) lines. During
hemodialysis, plasma C3a level rose from a mean 401 nglml (±
63), (normal < 200) to a peak of 6,325 ng/ml(± 1103) in patients
undergoing hernodialysis with cuprophan devices, without sta-
tistically significant differences between the two cuprophan
devices. In patients using cellulose acetate devices, the baseline
Fig. 2. Photographs of immunoelectrophoretic gels. Cellulose acetate
engenders less C3 conversion than does Cuprophan. Normal plasma
(top) shows a single arc of C3, while zymosan-activated plasma (second
panel) shows a very strong, anodally-displaced arc of C3 conversion
product (arrowhead). Plasma incubated with cuprophan (third panel)
also shows an arc ofconversion products, which is denser than the arc
seen with cellulose-acetate-incubated plasma (bottom panel), but less
dense than that obtained with zymosan-incubated plasma. Results were
concordant for six plasma donors.
level was similar at 426 ng/ml (± 43), but the mean peak was
only 3,637 (± 605), (P < 0.05).Of particular interest, the rate of
rise of C3a concentration was similar in the first 5 mm, but
rapidly fell off in patients using cellulose acetate dialyzers; in
patients using Cuprophan dialyzers, the level continued to rise,
and a slower fall-off in level occurred somewhat later (Fig. 3).
Concordant with the results using granulocyte aggregometry,
the levels of immunoassayable C5a accumulating in the pa-
tients' circulation were unimpressive and not statistically differ-
ent between the two dialyzers (Fig. 3).
Lactoferrin levels. While a difference in the degree of neutro-
penia certainly suggested that granulocyte activation was less
with the newer dialyzer, it remained possible that that differ-
ence was an expression of a difference in endothelial adhesivity
for granulocytes rather than a difference in the degree of
activation of the granulocytes themselves. Since lactoferrin is a
granulocyte release product with a long enough half-life to be
assayable as an index of granulocyte activation [19], we mea-
sured its plasma concentration in patients undergoing dialysis
with the two devices. Concordant with the other results, we
found that only 5 of 12 patients undergoing hemodialysis with
cellulose acetate devices developed abnormal lactoferrin levels,
in contrast to 12 of 13 patients being dialyzed with cuprophan
devices (x2 = 7.35; 0.001 < P < 0.01). Further, in 10 of 11
patients for whom adequate paired data were available, the
peak lactoferrin level was higher during cuprophan than during
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Time Cellulose acetateb Cuprophan P
0 0.71 (0.18) 1.32 (0.41)
5 mm 2.42 (0.58) 2.86 (0.36)
10mm 2.30 (0.60) 3.19 (0.45)
30 mm 2.87 (0.61) 4.50 (0.52) < 0.05
Peak 3.19 (0.68) 4.67 (0.50) < 0.05
At all time points, higher lactoferrin levels were observed in
patients undergoing cuprophan membrane hemodialysis than in patients
using cellulose acetate devices. The difference is statistically significant
at 30 mm and the peak. Further, since each patient was intended to
serve as his own control, paired data were available for 11 of 13
patients; paired data analysis yielded statistical significance also at S
and 10 mm, and confirmed (and extended to the P < 0.01 level) that at
30 mm and the peak. Finally, the proportion of abnormal results was
significantly greater in the cuprophan group.
b Figures in parentheses are SEM.
cellulose acetate hemodialysis (peak = 1.94 ig/ml; P = 0.005,
Table 2).
Discussion
A possible role of the complement-stimulated granulocyte in
a variety of disease states has been a source of a great deal of
interest and some controversy in the past decade. While study
of this has included such diverse states as pancreatitis [20], the
adult respiratory distress syndrome [16] and hyperoxic toxicity
to the lungs [21], a major area of interest has continued to be
extracorporeal circulations, in which many of the early data
were generated [3, 4, 6, 22—241. Although the clinical import of
dialysis-associated pulmonary dysfunction itself may be ar-
gued, we continue to find the hypothesis attractive that comple-
ment activation and resultant granulocyte activation during
hemodialysis may contribute to some of its occasional symp-
toms and complications.
In the current study, we compared two hemodialyzers with
claimed differences in "blood compatibility." Studying hemodi-
alysis patients in a blinded prospective fashion, we found that
intradialytic symptoms were consistently and statistically sig-
nificantly less severe when cellulose acetate hemodialyzers
were used than when cuprophan dialyzers were used. We found
this to correlate with a lesser degree of neutropenia, a lesser
potency of cellulose acetate to activate plasma complement in
vitro, lower plasma levels during cellulose acetate hemodialysis
of the complement-derived anaphylatoxin C3a, and a lower
level in those patients of the granulocyte release product
lactoferrin. We conclude that the cellulose acetate device is in
fact better tolerated in terms of patient symptoms than the
cuprophan device, and we postulate that this benefit likely
derives from the now demonstrated lesser ability of the cellu-
lose acetate device to activate complement and in turn to
activate granulocytes.
The time course of plasma C3a levels during hemodialysis is
of particular interest (Fig. 3). The level rose abruptly and in
parallel for the two dialyzers under study. However, the
patients using cellulose acetate devices experienced rapid peaks
in C3a level and a rapid fall-off, while the patients using
cuprophan devices had a slower peak and slower fall-off. A
variety of evidence suggests that the alternative pathway of
complement activation may in fact be self-activating, and the
E
4000
2000
Time on dialysis, mm
Fig. 3. C3a and C5a levels during early hemodia/ysis. The C3a level
proved to be a more sensitive detector of complement activation in this
context than did the C5a level and showed the greatest activation during
the use of cuprophan devices. Data displayed are mean values for 13
patients in each group; SE for the peak values are provided in Results.
Peak values and values at 10 and 30 mm are different at P < 0.01 by
Student's paired t test.
property that makes a surface an "activator" may be that it is a
surface on which the inhibitors of alternative pathway activa-
tion function poorly [25]. Another factor that appears to be of
import is the density of deposition of C3b upon a surface [26];
that is, a surface which binds C3b well would be expected to be
a more potent activator than one which binds C3b poorly. It is
attractive to speculate from the time course of activation that
the cellulose acetate membrane more rapidly becomes saturat-
ed with C3 fragments—perhaps by having fewer suitable bind-
ing sites—and in losing its ability to bind additional C3b also
loses its ability to activate plasma complement further.
As a preliminary test of this hypothesis, an estimate of the
amount of C3b bound to each membrane was obtained in the
following manner: Finely minced membrane was prepared from
a cellulose acetate dialyzer and a cuprophan dialyzer. Each was
incubated in fresh plasma, washed extensively, then incubated
with commercial caprine, horseradish-peroxidase-conjugated
IgG directed against human C3 (Cappel Laboratories, Cochran-
ville, Pennsylvania). After extensive washing, these fragments
were used as a source of insoluble peroxidase in the H202-
mediated oxidation of aminoantipyrine [271. The cuprophan
Table 2. Plasma lactoferrin levels (g/ml) during hemodialysis
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membrane so treated developed 85 mU peroxidase activity per
gram, while the cellulose acetate membrane developed only 38
mU/g; this suggests that cuprophan was capable of binding
more C3-related protein than was cellulose acetate.
It is also of interest that the increases in plasma C5a concen-
tration were unimpressive, whether measured by bioassay or
radioimmunoassay, and were inadequate to distinguish between
the two dialyzers in clinical use. This would superficially seem
to contradict the readily apparent difference in C5a generation
on in vitro incubation of the fibers with plasma. However, C5a
desarginine has a very short functional half-life in vivo [28—301.
Therefore, clinical elevations in plasma C5a level are likely to
occur only when complement activation is quite brisk or when
something has led to failure of the clearance mechanisms, and
when sample timing has been precisely appropriate.
It is noteworthy that three cuprophan hemodialysis sessions
were interrupted for symptoms during the blinded trial. This is a
considerably higher incidence of such severe intolerance than
would normally be seen, even when one considers that some
patients underwent two dialyses with cuprophan—to complete
the lactoferrin data—so that the total number of runs was 24
rather than the 13 of the initial symptomatic evaluation. In part,
this may derive from the fact that this was a blinded trial, and
patients were aware of the possibility that they were being
treated with a device which would be proven by the trial to be
less well tolerated; thus, they may have complained of symp-
toms at a lower level of severity than they would have if they
believed that no options existed. More interesting and attractive
to us, however, is the possibility that this derives from our
patient selection; that is, the patients entered into the random-
ization were patients who chronically underwent hemodialysis
with cellulose acetate membranes (although this was not be-
cause of prior intolerance of cuprophan), If one assumes that
the adverse reactions are mediated by substances (including,
but perhaps not limited to the complement anaphylatoxins)
which are cleared by inducible clearance mechanisms, such
patients might be expected to have a lesser degree of induction
of their clearance mechanisms than would patients chronically
hemodialyzed with cuprophan; they would then be expected to
have a lesser ability to deal with the anaphylatoxin load of
cellophane membrane hemodialysis than would patients chroni-
cally undergoing hemodialysis with cuprophan. The validation
of this hypothesis awaits further testing.
Our studies support the use of cellulose acetate hemodialysis
membranes in patients who have frequent intradialytic symp-
toms with cuprophan membranes. However, it would be prema-
ture to conclude that cellulose acetate has rendered cuprophan
obsolete. Confirmation of the current findings, as well as a
longer clinical experience with cellulose acetate devices, will be
needed to clarify the place of the new dialyzers in routine
clinical practice.
We propose from these studies that the ability to activate
complement is an important determinant of biocompatibility of
membranes, and that continued attempts to devise membranes
and devices which do not potently activate complement would
bear fruit in improved clinical tolerance.
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